ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 902

Evidence for Inhibition of Osteoclastogenesis By Cytomegalovirus Infection: Implication in RA Bone Erosion and Identification of a Cellular Protein As a Therapeutic Target

Benjamin Rauwel1, Michel Baron1, Adeline Ruyssen-Witrand2, Delphine Nigon3, Yannick Degboé2, Jacques Izopet1, Alain Cantagrel1 and Jean-Luc Davignon1, 1CPTP, INSERM UMR 1043, Toulouse, France, 2Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, 3Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: osteoclastogenesis, Rheumatoid arthritis (RA), treatment and viruses

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Biology and Pathology of Bone and Joint

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Exacerbated differentiation of monocytes into osteoclasts (OC) contributes to the pathogenesis of rheumatoid arthritis (RA) resulting in severe bone erosion and functional damage. Osteoclastogenesis is initiated by M-CSF and RANKL signalization through their respective receptor CSF-1R and RANK. In vitro, it has been demonstrated that Human Cytomegalovirus (HCMV) infection inhibits macrophage differentiation through a down regulation of numerous receptor, including CSF-1R [Frascaroli et al., J. Immunol., (2009)]. As CSF-1R signaling is essential to induce RANK expression, the key receptor for osteoclast differentiation, we studied the effect of HCMV infection on osteoclastogenesis and evaluated the consequences of HCMV seropositivity on bone erosion evolution in a RA cohort.

Methods: Blood monocytes from healthy donors were purified by adherence selection and differentiated in osteoclast by recombinant M-CSF and RANKL (both at 50 ng/mL) during 12 days. After 24 hours of differentiation, pre-osteoclasts were infected with a HCMV clinical strain (VHL/E) at the m.o.i. of 3. Expression of cellular proteins CSF-1R, RANK, and “X-protein” (patent being filed) and viral protein (IE) expressions were studied by RT-qPCR, Western Blot, Flow Cytometry and fluorescence microscopy. OC differentiation was evaluated by manual counting after TRAP staining. Lentiviral transduction and Amaxa transfections were performed to over-express or inhibit the expression of “X-protein” and confirm its role.

We then analyzed patients from the French « ESPOIR » cohort, fulfilling the 2010 ACR/EULAR criteria for RA. We evaluated the correlation between HCMV serology status and structural involvement assessed by the modified Sharp score, at baseline and 1 year.

Results: We demonstrated for the first time that HCMV infection inhibits osteoclastogenesis. No osteoclast was observed in HCMV infected wells in vitro. We observed that HCMV infection inhibits CSF-1R and RANK mRNA and proteins expression in a viral replication dependent manner. We found that viral IE protein expression was followed by an increase of expression of the cellular “X-protein”. To confirm these observations, we over-expressed the “X protein” in monocytes and observed that CSF-1R, RANK and, as a result, osteoclastogenesis were completely inhibited. Knock-down experiment of “X protein” with shRNA lentiviral vectors blocked the inhibitory effect of HCMV on CSF-1R and RANK expression.

Analysis of the ESPOIR cohort, including 273 HCMV+ and 214 HCMV- RA patients, demonstrated that, although there was no difference at inclusion, HCMV seropositive patients displayed less severe bone erosion score in comparison with HCMV negative ones after one year (p=0.0151),thus providing a pathophysiological counterpart of our in vitro observations.

Conclusion: HCMV infection inhibits osteoclastogenesis through a mechanism involving “X-protein” and results in a protective effect on bone erosion during RA. Over expression of this “X-protein” inhibited OC differentiation and could be a new therapeutic target to limit bone erosion during chronic inflammatory disease such as RA and in osteoporosis.


Disclosure: B. Rauwel, None; M. Baron, None; A. Ruyssen-Witrand, None; D. Nigon, None; Y. Degboé, None; J. Izopet, None; A. Cantagrel, None; J. L. Davignon, None.

To cite this abstract in AMA style:

Rauwel B, Baron M, Ruyssen-Witrand A, Nigon D, Degboé Y, Izopet J, Cantagrel A, Davignon JL. Evidence for Inhibition of Osteoclastogenesis By Cytomegalovirus Infection: Implication in RA Bone Erosion and Identification of a Cellular Protein As a Therapeutic Target [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/evidence-for-inhibition-of-osteoclastogenesis-by-cytomegalovirus-infection-implication-in-ra-bone-erosion-and-identification-of-a-cellular-protein-as-a-therapeutic-target/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evidence-for-inhibition-of-osteoclastogenesis-by-cytomegalovirus-infection-implication-in-ra-bone-erosion-and-identification-of-a-cellular-protein-as-a-therapeutic-target/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology